AAPL   373.03 (+2.45%)
MSFT   210.71 (+2.16%)
AMZN   3,035.97 (+5.04%)
NVDA   392.46 (+2.07%)
CGC   16.97 (+3.16%)
BABA   238.33 (+6.59%)
TSLA   1,346.62 (+11.41%)
AMD   53.27 (+1.76%)
T   30.34 (+0.86%)
F   6.19 (+2.15%)
DIS   113.97 (+1.60%)
BAC   23.67 (+1.63%)
NFLX   494.41 (+3.67%)
BA   188.33 (+4.16%)
AAPL   373.03 (+2.45%)
MSFT   210.71 (+2.16%)
AMZN   3,035.97 (+5.04%)
NVDA   392.46 (+2.07%)
CGC   16.97 (+3.16%)
BABA   238.33 (+6.59%)
TSLA   1,346.62 (+11.41%)
AMD   53.27 (+1.76%)
T   30.34 (+0.86%)
F   6.19 (+2.15%)
DIS   113.97 (+1.60%)
BAC   23.67 (+1.63%)
NFLX   494.41 (+3.67%)
BA   188.33 (+4.16%)
AAPL   373.03 (+2.45%)
MSFT   210.71 (+2.16%)
AMZN   3,035.97 (+5.04%)
NVDA   392.46 (+2.07%)
CGC   16.97 (+3.16%)
BABA   238.33 (+6.59%)
TSLA   1,346.62 (+11.41%)
AMD   53.27 (+1.76%)
T   30.34 (+0.86%)
F   6.19 (+2.15%)
DIS   113.97 (+1.60%)
BAC   23.67 (+1.63%)
NFLX   494.41 (+3.67%)
BA   188.33 (+4.16%)
AAPL   373.03 (+2.45%)
MSFT   210.71 (+2.16%)
AMZN   3,035.97 (+5.04%)
NVDA   392.46 (+2.07%)
CGC   16.97 (+3.16%)
BABA   238.33 (+6.59%)
TSLA   1,346.62 (+11.41%)
AMD   53.27 (+1.76%)
T   30.34 (+0.86%)
F   6.19 (+2.15%)
DIS   113.97 (+1.60%)
BAC   23.67 (+1.63%)
NFLX   494.41 (+3.67%)
BA   188.33 (+4.16%)
Log in

CVE:GSDDevonian Health Group Stock Price, Forecast & News

C$0.18
0.00 (0.00 %)
(As of 07/6/2020 03:28 PM ET)
Add
Compare
Today's Range
C$0.19
Now: C$0.19
C$0.19
50-Day Range
C$0.12
MA: C$0.15
C$0.20
52-Week Range
C$0.09
Now: C$0.19
C$0.44
Volume2,500 shs
Average Volume21,566 shs
Market CapitalizationC$15.18 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Devonian Health Group Inc., a pharmaceutical company, engages in the development of botanical drugs. Its lead product candidate is Thykamine, which is in Phase II clinical trials for the treatment of ulcerative colitis and atopic dermatitis. It also develops value-added products for dermo-cosmetics. The company was incorporated in 2013 and is headquartered in Québec, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone450-937-6696

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$2.43 million
Cash FlowC$0.01 per share
Book ValueC$0.12 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$15.18 million
Next Earnings DateN/A
OptionableNot Optionable

Receive GSD News and Ratings via Email

Sign-up to receive the latest news and ratings for GSD and its competitors with MarketBeat's FREE daily newsletter.

Devonian Health Group (CVE:GSD) Frequently Asked Questions

How has Devonian Health Group's stock been impacted by COVID-19 (Coronavirus)?

Devonian Health Group's stock was trading at C$0.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, GSD shares have decreased by 15.9% and is now trading at C$0.19. View which stocks have been most impacted by Coronavirus.

Has Devonian Health Group been receiving favorable news coverage?

Media headlines about GSD stock have trended negative on Monday, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Devonian Health Group earned a news sentiment score of -2.1 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Devonian Health Group.

Who are some of Devonian Health Group's key competitors?

Who are Devonian Health Group's key executives?

Devonian Health Group's management team includes the following people:
  • Dr. Andre P. Boulet, Chairman, Pres, CEO & Sec. (Age 60)
  • Ms. Colette Laurin, CFO & Corp. Controller
  • Mr. Tarique Sayed, Sec. & Director

What is Devonian Health Group's stock symbol?

Devonian Health Group trades on the Canadian Venture Exchange (CVE) under the ticker symbol "GSD."

How do I buy shares of Devonian Health Group?

Shares of GSD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Devonian Health Group's stock price today?

One share of GSD stock can currently be purchased for approximately C$0.19.

How big of a company is Devonian Health Group?

Devonian Health Group has a market capitalization of C$15.18 million and generates C$2.43 million in revenue each year.

What is Devonian Health Group's official website?

The official website for Devonian Health Group is www.groupedevonian.com.

How can I contact Devonian Health Group?

The company can be reached via phone at 450-937-6696.

This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.